952424-09-8 Usage
Molecular structure
1-oxo-1,2,3,4-tetrahydroisoquinoline-7-sulfonyl chloride
A heterocyclic compound with a tetrahydroisoquinoline backbone and a sulfonyl chloride group attached to the 7-position.
3. Sulfonyl chloride derivative
A reactive chemical compound that contains the -SO2Cl functional group.
Reactivity
High
The presence of the sulfonyl chloride group makes the compound highly reactive, allowing it to be used in organic synthesis.
Use in organic synthesis
Introduction of the sulfonyl group
The compound can be used to introduce the sulfonyl group (-SO2) into other molecules, which is a common pharmacophore in bioactive compounds.
Potential applications
Pharmaceutical and agrochemical industries
Due to its reactivity and the presence of the sulfonyl group, the compound may have applications in the development of pharmaceuticals and agrochemicals.
Further research
Additional uses and applications
Ongoing research may reveal more uses and applications for 1-oxo-1,2,3,4-tetrahydroisoquinoline-7-sulfonyl chloride in various fields.
Check Digit Verification of cas no
The CAS Registry Mumber 952424-09-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,2,4,2 and 4 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 952424-09:
(8*9)+(7*5)+(6*2)+(5*4)+(4*2)+(3*4)+(2*0)+(1*9)=168
168 % 10 = 8
So 952424-09-8 is a valid CAS Registry Number.
952424-09-8Relevant articles and documents
Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector
Sari, Ozkan,Boucle, Sebastien,Cox, Bryan D.,Ozturk, Tugba,Russell, Olivia Ollinger,Bassit, Leda,Amblard, Franck,Schinazi, Raymond F.
, p. 407 - 421 (2017/07/10)
The synthesis of novel series of sulfamoylbenzamides as HBV capsid assembly effector is reported. The structure was divided into five parts which were independently modified as part of our lead optimization. All synthesized compounds were evaluated for their anti-HBV activity and toxicity in human hepatocytes, lymphocytes and other cells. Additionally, we assessed their effect on HBV cccDNA formation in an HBeAg reporter cell-based assay. Among the 27 compounds reported, several analogs exhibited submicromolar activities and significant reduction of HBeAg secretion. Selected compounds were studied under negative-stain electron microscopy for their ability to disrupt the HBV capsid formation. Structures were modeled into a binding site recently identified in the HBV capsid protein for similar molecules to rationalize the structure-activity relationships for this family of compounds.
ORGANIC COMPOUNDS
-
Page/Page column 194, (2008/06/13)
The present invention relates to compounds of the formula; and their use in therapy.
